Anavex Life Sciences Corp...

AI Score

XX

Unlock

8.70
-0.84 (-8.81%)
At close: Mar 28, 2025, 3:59 PM
8.81
1.26%
After-hours: Mar 28, 2025, 05:49 PM EDT
-8.81%
Bid 8.58
Market Cap 740.06M
Revenue (ttm) n/a
Net Income (ttm) -46.63M
EPS (ttm) -0.55
PE Ratio (ttm) -15.82
Forward PE 1.94
Analyst Buy
Ask 9.58
Volume 1,412,174
Avg. Volume (20D) 1,367,375
Open 9.41
Previous Close 9.54
Day's Range 8.63 - 9.53
52-Week Range 3.25 - 14.44
Beta 0.94

About AVXL

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinica...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 2, 2006
Employees 42
Stock Exchange NASDAQ
Ticker Symbol AVXL
Full Company Profile

Analyst Forecast

According to 3 analyst ratings, the average rating for AVXL stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 428.74% from the latest price.

Stock Forecasts
2 months ago
+8.21%
Anavex Life Sciences shares are trading higher aft... Unlock content with Pro Subscription
3 months ago
+29.55%
Anavex Life Sciences shares are trading higher after the company announced better-than-expected Q4 financial results.